These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 26176936)

  • 81. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

  • 82. COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging.
    Washko GR; Parraga G
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30337445
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Integrative methods for analyzing big data in precision medicine.
    Gligorijević V; Malod-Dognin N; Pržulj N
    Proteomics; 2016 Mar; 16(5):741-58. PubMed ID: 26677817
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical and molecular markers in COPD.
    Gonçalves I; Guimarães MJ; van Zeller M; Menezes F; Moita J; Simão P;
    Pulmonology; 2018; 24(4):250-259. PubMed ID: 29898875
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.
    Faner R; Agustí Á
    Ann Am Thorac Soc; 2016 Dec; 13 Suppl 2():S466-S470. PubMed ID: 28005422
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Recent insights into human bronchial proteomics - how are we progressing and what is next?
    Tan HW; Xu YM; Wu DD; Lau ATY
    Expert Rev Proteomics; 2018 Feb; 15(2):113-130. PubMed ID: 29260600
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD.
    Zhang Z; Wang J; Li Y; Liu F; Chen L; He S; Lin F; Wei X; Fang Y; Li Q; Zhou J; Lu W
    Respir Res; 2023 Mar; 24(1):73. PubMed ID: 36899372
    [TBL] [Abstract][Full Text] [Related]  

  • 88. From Systems Understanding to Personalized Medicine: Lessons and Recommendations Based on a Multidisciplinary and Translational Analysis of COPD.
    Roca J; Cano I; Gomez-Cabrero D; Tegnér J
    Methods Mol Biol; 2016; 1386():283-303. PubMed ID: 26677188
    [TBL] [Abstract][Full Text] [Related]  

  • 89. From proteomics to prescription-the search for COPD biomarkers.
    Nicholas BL; O'Connor CD; Djukanovic R
    COPD; 2009 Aug; 6(4):298-303. PubMed ID: 19811390
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Multiomics Data Triangulation for Asthma Candidate Biomarkers and Precision Medicine.
    Pecak M; Korošec P; Kunej T
    OMICS; 2018 Jun; 22(6):392-409. PubMed ID: 29927718
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Genetic profiling for disease stratification in chronic obstructive pulmonary disease and asthma.
    Rathnayake SNH; Van den Berge M; Faiz A
    Curr Opin Pulm Med; 2019 May; 25(3):317-322. PubMed ID: 30762612
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Developments for a growing Japanese patient population: facilitating new technologies for future health care.
    Kato H; Nishimura T; Ikeda N; Yamada T; Kondo T; Saijo N; Nishio K; Fujimoto J; Nomura M; Oda Y; Lindmark B; Maniwa J; Hibino H; Unno M; Ito T; Sawa Y; Tojo H; Egawa S; Edula G; Lopez M; Wigmore M; Inase N; Yoshizawa Y; Nomura F; Marko-Varga G
    J Proteomics; 2011 May; 74(6):759-64. PubMed ID: 21184850
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine.
    Kohler I; Hankemeier T; van der Graaf PH; Knibbe CAJ; van Hasselt JGC
    Eur J Pharm Sci; 2017 Nov; 109S():S15-S21. PubMed ID: 28502671
    [TBL] [Abstract][Full Text] [Related]  

  • 94. DNA methylation in chronic obstructive pulmonary disease.
    Huo X; Jin S; Wang Y; Ma L
    Epigenomics; 2021 Jul; 13(14):1145-1155. PubMed ID: 34142873
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Metabolomics - A wide-open door to personalized treatment in chronic heart failure?
    Marcinkiewicz-Siemion M; Ciborowski M; Kretowski A; Musial WJ; Kaminski KA
    Int J Cardiol; 2016 Sep; 219():156-63. PubMed ID: 27323342
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
    Umelo IA; Costanza B; Castronovo V
    Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparative proteomics analysis of patients with quick development and slow development Chronic Obstructive Pulmonary Disease (COPD).
    Li F; Xu D; Wang J; Jing J; Li Z; Jin X
    Life Sci; 2020 Sep; 256():117829. PubMed ID: 32454159
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Precision medicine and treatable traits in chronic airway diseases - where do we stand?
    Ulrik CS; Vijverberg S; Hanania NA; Diamant Z
    Curr Opin Pulm Med; 2020 Jan; 26(1):33-39. PubMed ID: 31644440
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Precision prevention: A focused response to shifting paradigms in healthcare.
    Ramos KS; Bowers EC; Tavera-Garcia MA; Ramos IN
    Exp Biol Med (Maywood); 2019 Mar; 244(3):207-212. PubMed ID: 30869554
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
    Agusti A; Barnes N; Cruz AA; Gibson PG; Heaney LG; Inoue H; Leather D; Martinez FJ; McDonald VM; Oppenheimer J; Papi A; Pavord ID; Thomas M; Walker S; Yates L
    Respir Med; 2021 Oct; 187():106572. PubMed ID: 34478992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.